Renal Cell Carcinoma

The FDA approved nivolumab in combination with cabozantinib as first-line treatment of patients with advanced renal cell carcinoma, according to a manufacturer-issued press release.

Each month, John Sweetenham, MD, and I review a stack of reports from conferences and the international literature for reporting in HemOnc Today.

The FDA granted priority review to nivolumab in combination with cabozantinib for treatment of advanced renal cell carcinoma.

Nivolumab plus cabozantinib conferred superior PFS, OS and response rates compared with sunitinib as a first-line treatment for advanced renal cell carcinoma, according to results of a phase 3 study presented at ESMO Virtual Congress 2020.

Cytoreductive nephrectomy may extend OS for a well-selected population of patients with metastatic renal cell carcinoma, according to study results published in Cancer.

The FDA granted breakthrough therapy designation to MK-6482 for the treatment of certain patients with von Hippel-Lindau disease-associated renal cell carcinoma, according to a press release from the agent’s manufacturer.

The release of findings from the Checkmate-214 study produced multiple changes for specialists in renal cell carcinoma. Chung-Han Lee, MD, PhD, medical oncologist at Memorial Sloan Kettering Cancer Center, spoke with Healio about CheckMate-214 findings, clinical relevance, FDA approvals of TKI/IO regimens and possible novel agents.

Percutaneous cryoablation appeared safe and improved 10-year survival outcomes compared with partial or radical nephrectomy among patients with early-stage renal cell carcinoma, according to study results published in Radiology.

Choosing the best treatment for a patient with renal cell carcinoma involves a thorough assessment of the potential advantages and drawbacks of each targeted and immune therapy option based on the patient’s risk level and adjustment based on response to frontline treatment.

The COVID-19 pandemic presents unique challenges to renal cell carcinoma patients, especially concerning treatment. Healio spoke with Matthew R. Zibelman, MD, assistant professor, department of hematology/oncology, Fox Chase Cancer Center, spoke with Healio about renal cell carcinoma treatment during the COVID-19 pandemic, the FDA approval of pembrolizumab and use of telemedicine.